Sangamo Therapeutics Company
Sangamo researches, develops and commercializes engineered DNA-binding proteins for the development of novel therapeutic strategies.
Technology:
Biotechnology, CAR-T therapy, Cell-based gene therapy, Genetics, Pharmaceutical, Stem cell therapy, Stem cells therapy, Therapeutics
Industry:
End-to-end Drug Development, Public
Headquarters:
Richmond, California, United States
Founded Date:
1995-01-01
Employees Number:
251-500
Funding Status:
IPO
Acquisitions Number:
2
Investors Number:
3
Total Funding:
522100000
Estimated Revenue:
$10M to $50M
Last Funding Date:
2019-04-03
Last Funding Type:
Post-IPO Equity
Register and Claim Ownership